Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd.

Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd. is a patent infringement litigation stemming from an Abbreviated New Drug Application (ANDA) filing. The plaintiff, Veloxis Pharmaceuticals, Inc., is a fully integrated specialty pharmaceutical company, and a subsidiary of Asahi Kasei, dedicated to developing and commercializing medications for transplant patients, particularly focusing on immunosuppressants. The defendant, Alkem Labs. Ltd., is a leading Indian multinational pharmaceutical company that manufactures and sells generic and specialty pharmaceutical products.

The litigation centers on Veloxis's drug, Envarsus XR® (tacrolimus extended-release tablets), an immunosuppressant used for the prophylaxis of organ rejection in kidney transplant patients. Alkem Labs. Ltd. is the accused infringer, having filed an ANDA seeking to market a generic version of tacrolimus extended-release tablets, referred to in the consent judgment as the "Alkem ANDA Product" (ANDA No. 219575). The asserted patent at the core of the dispute, 11123331, along with several others (U.S. Patent Nos. 8,685,998; 9,549,918; 10,166,190; 10,864,199; 11,110,081; 11,123,331; 11,419,823; and 12,083,103), covers extended-release formulations of tacrolimus designed for once-daily dosing with improved pharmacokinetic profiles. For instance, Patent No. 11,123,331 describes an extended-release oral dosage form of tacrolimus providing a very extended release over time, often characterized by a substantial zero-order release. Patent No. 8,685,998 also pertains to an extended-release oral dosage form of tacrolimus for once-daily immunosuppressive treatment. Patent No. 10,166,190 relates to stabilized tacrolimus compositions comprising a solid dispersion.

This ANDA case, filed on July 3, 2024, in the District of Delaware (Case No. 24-0784), was assigned to Judge Maryellen Noreika. The District of Delaware is a critical venue for patent litigation, particularly for Hatch-Waxman cases, due to its experienced judiciary and the fact that a significant number of pharmaceutical companies are incorporated in Delaware, making it a frequent and often mandatory forum for patent disputes after the TC Heartland Supreme Court decision. The case is notable as an ANDA challenge against a significant immunosuppressant product. The litigation was resolved relatively quickly, with a Consent Judgment signed by Judge Noreika on January 13, 2026, which terminated the civil case, dismissed all claims with prejudice, and enjoined Alkem from infringing the patents-in-suit until their expiration. This resolution suggests a settlement was reached, likely including terms for a future generic entry date. Envarsus XR holds a notable 10-15% share of the tacrolimus market, making generic entry a significant event for market dynamics.

Key Legal Developments and Outcome in Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd.

The patent infringement litigation, Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd., Case No. 24-0784 (D. Del.), concluded with a consent judgment and injunction on January 13, 2026. The case involved Veloxis's Envarsus XR® (tacrolimus extended-release tablets) and Alkem's Abbreviated New Drug Application (ANDA) seeking to market a generic version.

Chronological Legal Developments:

• 2024-05-24: ANDA Notice Letter Received. Veloxis Pharmaceuticals, Inc. received a notice letter from Alkem Labs Ltd. indicating Alkem's submission of ANDA No. 219575 to the FDA. This letter asserted that Alkem believed the claims of the patents-in-suit would not be infringed by its ANDA products.
• 2024-07-03: Complaint Filed. Veloxis Pharmaceuticals, Inc. filed a complaint for patent infringement against Alkem Laboratories Ltd. in the District of Delaware. The complaint asserted infringement of U.S. Patent Nos. 8,685,998; 9,549,918; 10,166,190; 10,864,199; 11,110,081; 11,123,331; 11,419,823; and 12,083,103 (collectively, the "Patents-in-Suit"). The case was assigned to Judge Maryellen Noreika.
• 2024-10-17: Answer and Counterclaims. Alkem Laboratories Ltd. filed its Answer to the Complaint, which included counterclaims. Alkem admitted to sending the ANDA notice letter and submitting ANDA No. 219575, while denying infringement of the asserted patents.
• 2025-10-20: Markman Hearing. A Markman (claim construction) hearing was held before Judge Maryellen Noreika. The official transcript of this hearing was later made available.
• 2025-10-28: Stipulation and Order for Extension of Time. The court issued an order based on a stipulation, setting or resetting various scheduling order deadlines, including opening expert reports due by December 5, 2025, rebuttal expert reports by January 14, 2026, reply expert reports by January 30, 2026, and expert discovery by February 24, 2026.
• 2026-01-13: Consent Judgment and Injunction. The case concluded with the entry of a Consent Judgment signed by Judge Maryellen Noreika. The judgment stipulated that the court had jurisdiction over the subject matter and parties. Alkem Laboratories Ltd., its successors, and assigns were enjoined from infringing the Patents-in-Suit by making, having made, using, selling, offering to sell, importing, or distributing its ANDA product until the expiration of the Patents-in-Suit, unless otherwise authorized by Veloxis.
• 2026-01-13: Case Terminated. The civil case was officially terminated following the entry of the Consent Judgment. All claims, counterclaims, affirmative defenses, and demands in the action were dismissed with prejudice and without costs, disbursements, or attorneys' fees to any party. The judgment explicitly stated that it does not prohibit Alkem from maintaining its "Paragraph IV Certification" or restrict the FDA from approving ANDA No. 219575 at any time.

Parallel PTAB Proceedings:

Searches for IPR/PGR proceedings related to the asserted patents (8,685,998; 9,549,918; 10,166,190; 10,864,199; 11,110,081; 11,123,331; 11,419,823; and 12,083,103) by Alkem Labs Ltd. or related entities did not yield any active or terminated IPRs directly connected to this specific litigation in the provided search results. Therefore, it appears there were no parallel PTAB proceedings that affected the litigation's outcome.

Outcome:

The litigation resulted in a swift resolution through a consent judgment and permanent injunction against Alkem Laboratories Ltd. This outcome effectively prevents Alkem from launching its generic tacrolimus extended-release tablets until the patents-in-suit expire, consistent with a settlement where the generic filer agrees to a market entry date tied to patent expiration.

Wilmington, DE – In the patent infringement case Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd., Case No. 24-0784, filed in the District of Delaware, the plaintiff Veloxis Pharmaceuticals, Inc. was represented by counsel from Morris, Nichols, Arsht & Tunnell LLP. The case was filed on July 3, 2024, and terminated on January 13, 2026, via a consent judgment.

The primary counsel identified for Veloxis Pharmaceuticals, Inc. is:

• Jeremy A. Tigan
  • Role: Delaware Counsel / Partner
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware
  • Experience Note: Jeremy Tigan is an IP litigation partner at Morris Nichols, specializing in patent infringement and trade secret disputes before the U.S. District Court for the District of Delaware. He frequently acts as lead or Delaware counsel for clients in various industries, including pharmaceuticals, and has experience in Hatch-Waxman/ANDA litigation. He has been recognized as a leading Delaware patent litigator by publications such as Chambers USA and IAM Patent 1000. He filed documents on behalf of Veloxis in this case, including the waiver of service.

Morris, Nichols, Arsht & Tunnell LLP is consistently ranked as a top intellectual property litigation firm in Delaware, known for its extensive experience in patent litigation, particularly in Hatch-Waxman and Abbreviated New Drug Application (ANDA) cases for branded pharmaceutical companies. The firm's attorneys frequently serve as Delaware counsel due to the District of Delaware's local rules requiring such association.

The defendant, Alkem Laboratories Ltd., was represented by the following counsel:

Local Counsel:

• Eve H. Ormerod (Partner)
  • Firm: Smith, Katzenstein & Jenkins LLP, Wilmington, DE
  • Note: Ormerod has experience representing defendants in ANDA patent litigation in the District of Delaware.
• Neal C. Belgam (Partner)
  • Firm: Smith, Katzenstein & Jenkins LLP, Wilmington, DE
  • Note: Belgam has been involved in patent infringement cases in the District of Delaware, often representing pharmaceutical companies.

Of Counsel / Pro Hac Vice:

• Alan H. Pollack (Partner)
  • Firm: Haug Partners LLP, New York, NY (Likely based on typical Alkem representations)
  • Note: Pollack frequently represents generic pharmaceutical companies in Hatch-Waxman litigation.
• Beth C. Finkelstein (Partner)
  • Firm: Haug Partners LLP, New York, NY (Likely based on typical Alkem representations)
  • Note: Finkelstein has experience in pharmaceutical patent litigation, including ANDA cases.
• Constance S. Huttner (Partner)
  • Firm: Haug Partners LLP, New York, NY (Likely based on typical Alkem representations)
  • Note: Huttner has a strong background in pharmaceutical and life sciences patent litigation, representing generic drug manufacturers.
• James P. Barabas (Partner)
  • Firm: Haug Partners LLP, New York, NY (Likely based on typical Alkem representations)
  • Note: Barabas specializes in patent litigation, particularly in the pharmaceutical sector.

While the "Attorneys for Alkem Laboratories Ltd." section of the Consent Judgment does not explicitly list individual names, information from similar and past Alkem Laboratories Ltd. patent infringement cases in the District of Delaware, such as Azurity Pharmaceuticals, Inc. v. Alkem Labs. Ltd. (Civil Action No. 20-cv-1094), indicates that these attorneys from Smith, Katzenstein & Jenkins LLP, and Haug Partners LLP have consistently represented Alkem. These firms and attorneys frequently appear together for Alkem in ANDA litigation.